Impact of surfactant protein D, interleukin-5, and eosinophilia on Cryptococcosis.

Abstract

Cryptococcus neoformans is an opportunistic fungal pathogen that initiates infection following inhalation. As a result, the pulmonary immune response provides a first line of defense against C. neoformans. Surfactant protein D (SP-D) is an important regulator of pulmonary immune responses and is typically host protective against bacterial and viral respiratory infections. However, SP-D is not protective against C. neoformans. This is evidenced by previous work from our laboratory demonstrating that SP-D-deficient mice infected with C. neoformans have a lower fungal burden and live longer than wild-type (WT) control animals. We hypothesized that SP-D alters susceptibility to C. neoformans by dysregulating the innate pulmonary immune response following infection. Thus, inflammatory cells and cytokines were compared in the bronchoalveolar lavage fluid from WT and SP-D(-/-) mice after C. neoformans infection. Postinfection, mice lacking SP-D have reduced eosinophil infiltration and interleukin-5 (IL-5) in lung lavage fluid. To further explore the interplay of SP-D, eosinophils, and IL-5, mice expressing altered levels of eosinophils and/or IL-5 were infected with C. neoformans to assess the role of these innate immune mediators. IL-5-overexpressing mice have increased pulmonary eosinophilia and are more susceptible to C. neoformans infection than WT mice. Furthermore, susceptibility of SP-D(-/-) mice to C. neoformans infection could be restored to the level of WT mice by increasing IL-5 and eosinophils by crossing the IL-5-overexpressing mice with SP-D(-/-) mice. Together, these studies support the conclusion that SP-D increases susceptibility to C. neoformans infection by promoting C. neoformans-driven pulmonary IL-5 and eosinophil infiltration.

Department

Description

Provenance

Subjects

Lung, Bronchoalveolar Lavage Fluid, Animals, Mice, Inbred C57BL, Mice, Knockout, Mice, Cryptococcus neoformans, Cryptococcosis, Eosinophilia, Disease Models, Animal, Pulmonary Surfactant-Associated Protein D, Interleukin-5, Female, Male

Citation

Published Version (Please cite this version)

10.1128/iai.00855-13

Publication Info

Holmer, Stephanie M, Kathy S Evans, Yohannes G Asfaw, Divey Saini, Wiley A Schell, Julie G Ledford, Richard Frothingham, Jo Rae Wright, et al. (2014). Impact of surfactant protein D, interleukin-5, and eosinophilia on Cryptococcosis. Infection and immunity, 82(2). pp. 683–693. 10.1128/iai.00855-13 Retrieved from https://hdl.handle.net/10161/32001.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Schell

Wiley Alexander Schell

Associate Professor Emeritus in Medicine
Frothingham

Richard Frothingham

Associate Professor of Medicine

Dr. Frothingham is the principal investigator of a research laboratory which studies Mycobacterium tuberculosis, the cause of tuberculosis, and Mycobacterium avium, a closely related bacterium causing serious infections in AIDS patients. We are pursuing two current projects.

The first project aims to develop vaccines against M. avium and M. tuberculosis. We inject mice with candidate plasmid DNA vaccines which produce bacterial proteins in mouse muscle. We use a variety of DNA adjuvants to modify the immune response. We hope to use DNA vaccination to protect against new infections and to modify the course of existing infections. We also hope to identify correlates of vaccine-induced protective immunity.

The second project uses variations in bacterial DNA sequences to identify species and strains. Dr. Frothingham was part of a team of four Duke scientists who used DNA sequence analysis to identify the cause of Whipple's disease. He also identified used DNA sequence to identify a particular group of M. avium strains which cause disseminated infections in AIDS patients. We recently developed a new tuberculosis typing method using variable numbers of tandem DNA repeats. We are applying this new typing method in national and international collaborations.

Dr. Frothingham does not currently conduct clinical trials.

Special areas of expertise include tuberculosis, mycobacteria, strain differentiation, DNA vaccination, and pyrazinamide.

Key words: tuberculosis, mycobacteria, Mycobacterium tuberculosis, Mycobacterium avium, DNA vaccines, tandem repeat DNA, pyrazinamide, mouse

Perfect

John Robert Perfect

James B. Duke Distinguished Professor of Medicine

Research in my laboratory focuses around several aspects of medical mycology. We are investigating antifungal agents (new and old) in animal models of candida and cryptococcal infections. We have examined clinical correlation of in vitro antifungal susceptibility testing and with in vivo outcome. Our basic science project examines the molecular pathogenesis of cryptococcal infections. We have developed a molecular foundation for C. neoformans, including transformation systems, gene disruptions, differential gene expression screens, and cloning pathogenesis genes. The goal of this work is to use C. neoformans as a model yeast system to identify molecular targets for antifungal drug development. There are a series of clinical trials in fungal infections which are being coordinated through this laboratory and my work also includes a series of antibiotic trials in various aspects of infections. Finally, we have now been awarded a NIH sponsored Mycology Unit for 5 years with 6 senior investigators which is focused on C. neoformans as a pathogenic model system, but will include multiple areas of medical mycology from diagnosis to treatment.


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.